Form 8-K

8-K — DuPont de Nemours, Inc.

Accession: 0001666700-26-000049

Filed: 2026-08-04

Period: 2026-08-04

CIK: 0001666700

SIC: 2821 (PLASTICS, MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — dd-20260804.htm (Primary)

EX-99.1 (exhibit991enrschedules-2q26.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: dd-20260804.htm · Sequence: 1

dd-20260804

0001666700false00016667002026-08-042026-08-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2026

DuPont de Nemours, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38196

81-1224539

(State or other jurisdiction of

incorporation) (Commission file number)

(IRS Employer Identification No.)

974 Centre Road, Building 730 Wilmington, Delaware 19805

(Address of Principal Executive Offices)

(Zip Code)

(302) 295-5783

(Registrant’s Telephone Number, Including Area Code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, par value $0.01 per share DD New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Section 2 - Financial Information

Item 2.02 Results of Operations and Financial Condition.

On August 4, 2026, DuPont de Nemours, Inc. (the "Company") issued a press release, attached as Exhibit 99.1, and incorporated herein by reference, announcing results for the second quarter 2026.

The information contained in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of Section 18. Furthermore, the information contained in this report shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1

Press release issued by DuPont de Nemours, Inc. on August 4, 2026, announcing results for the second quarter 2026.

104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DUPONT DE NEMOURS, INC.

Registrant

Date: August 4, 2026

By: /s/ MADELEINE G. BARBER

Name: Madeleine G. Barber

Title: Vice President of Tax, Controller and Chief Accounting Officer

EX-99.1

Filename: exhibit991enrschedules-2q26.htm · Sequence: 2

Document

Exhibit 99.1

DuPont Reports Second Quarter 2026 Results

Exceeds Second Quarter 2026 Guidance

Raises Full Year 2026 Guidance

Second Quarter 2026 Highlights

•Net Sales of $1.8 billion increased 4%; organic sales increased 4% versus year-ago period

•GAAP Income from continuing operations of $191 million; operating EBITDA of $448 million

• GAAP EPS from continuing operations of $1.37; adjusted EPS of $1.88

• Cash provided by operating activities from continuing operations of $400 million; transaction-adjusted free cash flow of $326 million representing 127% conversion

• Announces intent to repurchase $250 million of shares in the third quarter

• Announces the Company’s Global Industry Classification Standard (GICS) code has changed to Industrials effective July 31, 2026

WILMINGTON, Del., Aug. 4, 2026 - DuPont (NYSE: DD) announced its financial results(1) for the second quarter ended June 30, 2026 and raised financial guidance for the full year 2026.

“We delivered another strong quarter, exceeding our financial guidance and demonstrating our focus on consistent execution” said Lori Koch, DuPont Chief Executive Officer. “Mid-single digit organic growth, strong margin expansion, coupled with robust adjusted EPS growth and free cash flow generation underscore the strength of our market-leading businesses and reflect disciplined execution of our strategic priorities, supported by our ongoing focus on excellence and productivity.”

“We are delivering on our commitments, creating value for all of our key stakeholders and further strengthening the foundation for sustainable, long-term profitable growth,” Koch concluded.

Second Quarter 2026 Consolidated Results(1)

Dollars in millions, except EPS

2Q’26

2Q’25

Change

vs. 2Q’25

Organic Sales (2)

vs. 2Q’25

Net sales $1,819 $1,749 4% 4%

GAAP Income from continuing operations $191 $24 n.m.

Operating EBITDA(2)

$448 $423 6%

Operating EBITDA margin(2) %

24.6 % 24.2 % 40 bps

GAAP EPS from continuing operations $1.37 $0.17 n.m.

Adjusted EPS(2)

$1.88 $1.27 48%

Cash provided by operating activities – cont. ops. $400 $74 n.m.

Transaction-adjusted free cash flow(2)

$326 $107 205%

(1)Results and cash flows are presented on a continuing operations basis. See page 6 for further information, including the basis of presentation included in this release.

(2)Organic sales, operating EBITDA, operating EBITDA margin, adjusted EPS, transaction-adjusted free cash flow and transaction-adjusted free cash flow conversion are non-GAAP measures and only reflect continuing operations. See page 6 for further discussion, including a definition of significant items. Reconciliation to the most directly comparable GAAP measure, including details of significant items begins on page 13 of this communication.

Net sales

•Net sales were up 4% on a 4% increase in organic sales.

• 4% organic sales growth in Healthcare & Water Technologies; 3% organic sales growth in Diversified Industrials.

GAAP Income from continuing operations

•GAAP Income/GAAP EPS from continuing operations improved on higher segment earnings and lower interest expense and transaction costs.

Operating EBITDA

•Operating EBITDA increased on organic growth and productivity.

Adjusted EPS

•Adjusted EPS increased on higher segment earnings, lower net interest expense and a lower tax rate.

Cash provided by operating activities from continuing operations

•Cash provided by operating activities from continuing operations in the quarter of $400 million, capital expenditures of $76 million and separation-related transaction costs and other payments of $2 million resulted in transaction-adjusted free cash flow and related conversion of $326 million and 127%, respectively.

Second Quarter 2026 Segment Highlights

Healthcare & Water Technologies

Dollars in millions

2Q’26

2Q’25

Change

vs. 2Q’25

Organic Sales(2)

vs. 2Q’25

Net sales $856 $817 5% 4%

Operating EBITDA $258 $248 4%

Operating EBITDA margin % 30.1 % 30.4 % (30) bps

Net sales

•Net sales increased 5% on organic sales growth of 4% and a currency benefit of 1%.

◦Healthcare Technologies sales up mid-single digits on an organic basis on broad-based growth led by personal protection and biopharma.

◦Water Technologies sales up low-single digits on an organic basis on continued strength in industrial water and semiconductor markets, partially offset by weakness in the Middle East.

Operating EBITDA

•Operating EBITDA increased on organic growth and productivity, partially offset by growth investments.

• Operating EBITDA margin of 30.1% decreased 30 basis points as organic growth and productivity were more than offset by less favorable mix and growth investments.

Diversified Industrials

Dollars in millions

2Q’26

2Q’25 Change

vs. 2Q’25

Organic Sales(2)

vs. 2Q’25

Net sales $963 $932 3% 3%

Operating EBITDA $213 $199 7%

Operating EBITDA margin % 22.1 % 21.4 % 70 bps

Net sales

•Net sales increased 3% on organic sales growth in the quarter.

◦Building Technologies sales up low-single digits on an organic basis due to growth in residential and non-residential construction markets.

◦Industrial Technologies sales up mid-single digits on an organic basis on continued strength in aerospace coupled with growth in electric vehicle applications.

Operating EBITDA

•Operating EBITDA and margin increased on organic growth, favorable mix and productivity.

2026 Financial Outlook

Dollars in millions, except EPS

2H'26E

Full Year 2026E

Net sales $3,660 - $3,690 $7,160 - $7,190

Operating EBITDA(2)

$890 - $910 $1,750 - $1,770

Adjusted EPS(2)

$3.65 - $3.80 $7.17 - $7.32

“Our strong execution and market-driven growth continue to translate into higher earnings and free cash flow generation. As a result of our second quarter outperformance, we are again raising the midpoint of our full-year 2026 operating EBITDA guidance to approximately $1.76 billion and adjusted EPS guidance to $7.24 per share, while increasing our expectation for organic sales growth to slightly above 4%,” said Antonella Franzen, DuPont Chief Financial Officer.

“With continued strength across healthcare, industrial water, and aerospace end-markets, we expect mid-single digit organic sales growth in the second half and remain focused on driving profitable growth and value creation for shareholders.” Franzen concluded.

Conference Call

The Company will host a live webcast of its quarterly earnings conference call with investors to discuss its results and business outlook beginning today at 8:00 a.m. ET. The slide presentation that accompanies the conference call will be posted on the DuPont’s Investor Relations Events and Presentations page. A replay of the webcast also will be available on the DuPont’s Investor Relations Events and Presentations page following the live event.

About DuPont

DuPont (NYSE: DD) is a global innovation leader, providing advanced solutions that help transform industries and improve everyday life across our key markets of healthcare, water, construction, and industrial. More information about the company, its businesses and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

For further information contact:

DuPont

Investors:

Ann Giancristoforo

ann.giancristoforo@dupont.com

Media:

Dan Turner

daniel.a.turner@dupont.com

DuPontTM and all products, unless otherwise noted, denoted with TM, SM or ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.

Overview

On May 26, 2026, DuPont’s Board of Directors announced a reverse stock split of the Company’s common stock, par value $0.01 per share, at a ratio of 1-for-3, as well as a reduction in the number of authorized shares of its common stock by a corresponding ratio (the "Reverse Stock Split"), as approved by shareholders. The Reverse Stock Split became effective on June 24, 2026. All share and share-related information presented in these interim Consolidated Financial Statements has been retroactively adjusted in all periods presented to reflect the decreased number of shares resulting from the Reverse Stock Split and related impacts.

On April 1, 2026, DuPont completed the sale of the Aramids business (the "Aramids Business" and the divestiture of the Aramids Business, the "Aramids Divestiture") to Arclin, a portfolio company of an affiliate of TJC LP for pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable in the principal amount of $300 million (the "Aramids Note Receivable") and a non-controlling common equity interest (the "Aramids Equity Consideration"), valued at $325 million, in New Arclin U.S. Holding Corp., which now owns the Arclin global materials business and the Aramids Business. The financial results of the divested Aramids Business are reflected in DuPont's interim Consolidated Financial Statements as discontinued operations, along with comparative periods.

On November 1, 2025, DuPont completed the separation of its semiconductor and interconnect solutions businesses (the "Electronics Business" and the separation of the Electronics Business, the “Electronics Separation”) into an independent public company, Qnity Electronics, Inc. ("Qnity"), by way of the distribution to DuPont's stockholders of record as of October 22, 2025 of all the issued and outstanding common stock of Qnity on November 1, 2025 (the "Qnity Distribution"). As a result, the financial results of the divested Electronics Business are reflected in DuPont's interim Consolidated Financial Statements as discontinued operations for all periods.

Cautionary Statement Regarding Forward-looking Statements

Certain statements in this release may be considered forward-looking statements, within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements often contain words such as “expect”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “see”, “will”, “would”, “target”, “outlook”, “stabilization”, “confident”, “preliminary”, “initial”, “continue”, “may”, “could”, “project”, “estimate”, “forecast” and similar expressions and variations or negatives of these words. All statements, other than statements of historical fact, are forward-looking statements. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements.

Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to (i) the ability to realize the intended benefits of the Electronics Separation and the Qnity Distribution, including achievement of the intended tax treatment, contractual allocation to, and assumption by Qnity of certain liabilities, including certain legacy liabilities with respect to per- and polyfluoroalkyl substances ("PFAS") and the possibility of disputes, litigation or unanticipated costs in connection with the Electronics Separation and Qnity Distribution; (ii) the impact of the Aramids Divestiture on DuPont’s balance sheet, financial condition and future results of operations; (iii) risks and costs related to the impact of the arrangement to share future eligible PFAS costs by and among DuPont, Corteva, Inc. and The Chemours Company, including the outcome of pending or future litigation related to PFAS or PFOA, which includes personal injury claims and natural resource damages claims; the extent and cost of ongoing and potential future remediation obligations; and changes in laws and regulations applicable to PFAS chemicals; (iv) the failure to realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with the Electronics Separation, the Aramids Divestiture and completed and future, if any, divestitures, mergers, acquisitions, and other portfolio management, productivity and infrastructure actions; (v) risks and uncertainties that are outside the Company’s control but adversely impact the overall environment in which DuPont, its customers and/or its suppliers operate, including changes in economic, political, regulatory, international trade, geopolitical, military conflicts, capital markets and other external conditions, including pandemics and responsive actions, as well as natural and other disasters or weather-related events; (vi) the ability to offset increases in cost of inputs, including raw materials, energy and logistics; (vii) the risks and uncertainties associated with continuing or expanding geopolitical conflicts or trade disputes or restrictions and responsive actions, new or increased tariffs or export controls, including on exports to China of U.S.-regulated products and technology; (viii) other risks to DuPont’s business and operations, including the risk of impairment; (ix) risks and uncertainties in connection with completing the $2 billion share buyback announced on November 6, 2025, including timeline, associated costs and the possibility that the authorization may be suspended or discontinued prior to completion; (x) the ability to realize the intended benefits of the Reverse Stock Split; (xi) the impact of the invalidation of certain tariffs imposed under the International Emergency Economic Powers Act and (xii) other risk factors discussed in DuPont’s most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Non-GAAP Financial Measures

Unless otherwise indicated, all financial metrics presented reflect continuing operations only.

This communication includes information that does not conform to accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont’s management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these Non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page 12. Non-GAAP measures included in this communication are defined below. The Company has not provided forward-looking U.S. GAAP financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of certain future events. These events include, among others, the impact of portfolio changes, including asset sales, mergers, acquisitions, and divestitures; contingent liabilities related to litigation, environmental and indemnifications matters; impairments and discrete tax items. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP results for the guidance period.

Key Terms

Significant Items

Significant items are items that arise outside the ordinary course of business for the Company and includes items for nonconsolidated affiliates, that the Company’s management believes may cause misinterpretation of underlying business and investment performance, both historical and future, based on a combination of some or all of the item’s size, unusual nature and infrequent occurrence. Management classifies as significant items certain costs and expenses associated with integration and separation activities related to transformational acquisitions and divestitures as they are considered unrelated to ongoing business performance. There were no significant items associated with nonconsolidated affiliates recorded for the three and six month periods ended June 30, 2026 and June 30, 2025.

Future Reimbursable Indirect Costs

Indirect costs, such as those related to corporate and shared service functions previously allocated to the separated Electronics Business and Aramids Business, do not meet the criteria for discontinued operations and are reported within continuing operations in all respective periods presented. The Company has, is, will or expects to be reimbursed in accordance with the applicable transition service agreements (“TSAs”) for the portion of indirect costs related to activities the Company is, will or expects to undertake on a transitional basis to support a) Qnity not beyond year end 2027 for services and 2040 for site leases and, b) the Aramids Business post the Aramids Divestiture, but not beyond 2028 (such indirect costs “Future Reimbursable Indirect Costs”). Services provided and costs reimbursed in accordance with the applicable TSAs include but are not limited to, costs associated with information technology services/support, product stewardship and regulatory support, facilities services, and shared property lease costs.

Future Reimbursable Indirect Costs do not meet the criteria for discontinued operations and therefore are included in both GAAP Net Income from Continuing Operations and in GAAP Cash provided by operating activities-continuing operations for all periods presented. Future Reimbursable Indirect Costs are excluded from Adjusted Earnings, Operating EBITDA and Transaction-Adjusted Free Cash Flow, each defined below. Such indirect costs that are not subject to future reimbursement are reported within continuing operations in Corporate and are included within Adjusted Earnings, Operating EBITDA, and Cash provided by operating activities-continuing operations.

Corporate DDOB Remediation Costs

Corporate DDOB Remediation Costs are environmental remediation costs, including certain investigate, remediate and restoration costs, associated with discontinued or divested operations, businesses or product lines (“Corporate DDOB Remediation Costs”). DDOB Remediation Costs are excluded from Adjusted Earnings and Operating EBITDA, as defined below, to provide better insight into the underlying business performance of the Company.

Non-GAAP Measure Definitions

Organic Sales

Organic Sales is defined as net sales excluding the impacts of currency and portfolio.

Adjusted Earnings

Adjusted Earnings is defined as income from continuing operations excluding the after-tax impact of significant items, after-tax impact of amortization expense of intangibles, the after-tax impact of non-operating pension / other post employment benefits (“OPEB”) credits / costs, Future Reimbursable Indirect Costs and Corporate DDOB Remediation Costs.

Adjusted Earnings is the numerator used in the calculation of Adjusted EPS, as well as the denominator in Adjusted Free Cash Flow Conversion.

Adjusted EPS

Adjusted EPS is defined as Adjusted Earnings per common share - diluted. Management estimates amortization expense in 2026 associated with intangibles to be about $275 million on a pre-tax basis, or approximately $1.54 per share.

Operating EBITDA, EBITDA Margin & Incremental Margin

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, Corporate DDOB Remediation Costs, and adjusted for significant items. Reconciliations of these measures are provided on the following pages.

Operating EBITDA Margin is defined as Operating EBITDA divided by Net Sales.

Incremental Margin is the change in Operating EBITDA divided by the change in Net Sales for the applicable period.

Adjusted Free Cash Flow & Adjusted Free Cash Flow Conversion

Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and excluding the impact of cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business liquidity. As a result, Adjusted Free Cash Flow represents cash that is available to the Company, after investing in its asset base, to fund obligations using the Company’s primary source of liquidity, cash provided by operating activities from continuing operations. Management believes Adjusted Free Cash Flow, even though it may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company’s cash flow and financial performance, and it is an integral measure used in the Company’s financial planning process. Management notes that there were no exclusions for items that are unusual in nature and/or infrequent in occurrence for the three and six month periods ended June 30, 2026.

Adjusted Free Cash Flow Conversion is defined as Adjusted Free Cash Flow divided by Adjusted Earnings. Management uses Adjusted Free Cash Flow Conversion as an indicator of our ability to convert earnings to cash.

Transaction Adjusted Free Cash Flow & Transaction Adjusted Free Cash Flow Conversion

Management believes supplemental non-GAAP financial measures including Transaction-Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow Conversion (each defined below) provide an integral view of information on the Company's underlying business performance during this period of transformational change. Management believes the Electronics Separation and Aramids Divestiture collectively represent a significant transformational change for the Company and separation-related transaction cost payments impact comparability to the Company’s continuing operations. Management believes Transaction-Adjusted Free Cash Flow, which may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company’s cash flow and financial performance, and it is an integral measure used in the Company’s financial planning process. These non-GAAP financial measures are not intended to represent residual cash flow for discretionary expenditures since other non-discretionary expenditures, such as mandatory debt service requirements, are not deducted from the measure.

Transaction-Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and removing the impact of separation-related transaction costs and other payment and cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business liquidity.

Transaction-Adjusted Free Cash Flow Conversion is defined as Transaction-Adjusted Free Cash Flow excluding separation-related transaction costs, divided by Adjusted Earnings.

Separation-related transaction costs and other payments include cash outflows directly associated with the Electronics Separation and the Aramids Divestiture. These costs include advisor and banking fees, payments related to establishing a new capital structure (including fees associated with interest rate swaps), capital expenditures required to facilitate physical asset separation, restructuring payments associated with senior leadership, and Future Reimbursable Indirect Costs, among other expenditures.

Future Reimbursable Indirect Costs are excluded from Adjusted Earnings and Operating EBITDA. To provide comparable data analysis, the Company has also adjusted payments associated with Future Reimbursable Indirect Costs within Separation-related transaction costs and other payments. This adjustment is intended to provide insight into the Company's underlying business performance. For the six months ended June 30, 2026, the Company adjusted $8 million associated with Future Reimbursable Indirect Costs within Separation-related transaction costs and other payments.

Additionally, $2 and $5 million were reflected in Separation-related transaction costs and other payments for the three and six month periods ended June 30, 2026, respectively, for capital expenditures incurred to complete the physical separation of shared locations.

Finally, $6 million of restructuring and short-term incentive program payments to former senior leadership were reflected in Separation-related transaction costs and other payments for the six month period ended June 30, 2026. These payments were reflected in other cash payments as they related to the establishment of the post-spin leadership structure.

DuPont de Nemours, Inc.

Consolidated Statements of Operations

Three Months Ended June 30, Six Months Ended

June 30,

In millions, except per share amounts (Unaudited) 2026 2025 2026 2025

Net sales $ 1,819 $ 1,749 $ 3,500 $ 3,361

Cost of sales 1,180 1,143 2,259 2,212

Research and development expenses 42 53 89 103

Selling, general and administrative expenses 269 262 524 496

Amortization of intangibles 68 74 136 149

Restructuring and asset related (benefits) charges - net (3) — 43 39

Acquisition, integration and separation costs 7 55 7 105

Equity in earnings (loss) of nonconsolidated affiliates 9 9 8 (6)

Sundry income (expense) - net 42 (9) 78 91

Interest expense 41 84 81 167

Income from continuing operations before income taxes $ 266 $ 78 $ 447 $ 175

Provision for income taxes on continuing operations 75 54 106 71

Income from continuing operations, net of tax $ 191 $ 24 $ 341 $ 104

(Loss) income from discontinued operations, net of tax (44) 46 (30) (615)

Net income (loss) $ 147 $ 70 $ 311 $ (511)

Net income attributable to noncontrolling interests 4 11 7 19

Net income (loss) available for DuPont common stockholders $ 143 $ 59 $ 304 $ (530)

Per common share data:

Earnings per common share from continuing operations - basic $ 1.38 $ 0.17 $ 2.45 $ 0.73

(Loss) earnings per common share from discontinued operations - basic (0.32) 0.25 (0.22) (4.53)

Earnings (loss) per common share - basic $ 1.05 $ 0.42 $ 2.23 $ (3.80)

Earnings per common share from continuing operations - diluted $ 1.37 $ 0.17 $ 2.43 $ 0.73

(Loss) earnings per common share from discontinued operations - diluted (0.32) 0.25 (0.22) (4.52)

Earnings (loss) per common share - diluted $ 1.05 $ 0.42 $ 2.22 $ (3.79)

Weighted-average common shares outstanding - basic 135.9 139.6 136.3 139.6

Weighted-average common shares outstanding - diluted 136.8 139.9 137.2 139.9

DuPont de Nemours, Inc.

Condensed Consolidated Balance Sheets

In millions, except share amounts (Unaudited) June 30, 2026 December 31, 2025

Assets

Current Assets

Cash and cash equivalents $ 1,740 $ 715

Restricted cash and cash equivalents 42 42

Accounts and notes receivable - net 1,751 1,669

Inventories 1,210 1,172

Prepaid and other current assets 113 121

Assets of discontinued operations — 1,856

Total current assets $ 4,856 $ 5,575

Property, plant and equipment - net of accumulated depreciation (June 30, 2026 - $3,694; December 31, 2025 - $3,565)

3,379 3,464

Other Assets

Goodwill 7,840 7,915

Other intangible assets 2,789 2,936

Investments and noncurrent receivables 981 432

Deferred income tax assets 221 282

Deferred charges and other assets 995 971

Total other assets $ 12,826 $ 12,536

Total Assets $ 21,061 $ 21,575

Liabilities and Equity

Current Liabilities

Short-term borrowings $ — $ 60

Accounts payable 978 995

Income taxes payable 53 54

Accrued and other current liabilities 970 882

Liabilities of discontinued operations — 314

Total current liabilities $ 2,001 $ 2,305

Long-Term Debt 3,125 3,134

Other Noncurrent Liabilities

Deferred income tax liabilities 295 405

Pension and other post-employment benefits - noncurrent 400 432

Other noncurrent obligations 1,359 1,196

Total other noncurrent liabilities $ 2,054 $ 2,033

Total Liabilities $ 7,180 $ 7,472

Commitments and contingent liabilities

Stockholders' Equity

Common stock (authorized 555,555,556 shares of $0.01 par value each; issued 2026: 135,038,855 shares; 2025: 136,398,482 shares)

1 1

Additional paid-in capital $ 38,710 38,721

Accumulated deficit (24,326) (24,278)

Accumulated other comprehensive loss (616) (525)

Total DuPont stockholders' equity $ 13,769 $ 13,919

Noncontrolling interests 112 184

Total equity $ 13,881 $ 14,103

Total Liabilities and Equity $ 21,061 $ 21,575

DuPont de Nemours, Inc.

Consolidated Statement of Cash Flows

Six Months Ended June 30,

In millions (Unaudited) 2026 2025

Operating Activities

Net income (loss) $ 311 $ (511)

Loss from discontinued operations (30) (615)

Net income from continuing operations $ 341 $ 104

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 309 326

Credit for deferred income tax and other tax related items 45 9

(Earnings) losses of nonconsolidated affiliates (in excess of) less than dividends received (6) 7

Net periodic pension benefit costs 6 2

Periodic benefit plan contributions (28) (23)

Restructuring and asset related charges - net 43 39

Interest rate swap gain — (51)

Stock based compensation 27 22

Donatelle contingent earn-out true-up (14) (12)

Other net (income) loss (2) 16

Changes in assets and liabilities, net of effects of acquired and divested companies:

Accounts and notes receivable (88) (213)

Inventories (29) (51)

Accounts payable 92 (19)

Other assets and liabilities, net (64) (5)

Cash provided by operating activities - continuing operations $ 632 $ 151

Investing Activities

Capital expenditures (178) (172)

Proceeds and adjustments to proceeds from sales of businesses, net of cash divested 1,158 —

Other investing activities, net 9 7

Cash provided by (used for) investing activities - continuing operations $ 989 $ (165)

Financing Activities

Changes in short-term borrowings (60) —

Purchases of common stock and forward contracts (275) —

Proceeds from issuance of Company stock 107 4

Employee taxes paid for share-based payment arrangements (22) (22)

Distributions to noncontrolling interests (11) (5)

Dividends paid to stockholders (163) (343)

Other financing activities, net (1) (7)

Cash used for financing activities - continuing operations $ (425) $ (373)

Cash Flows from Discontinued Operations

Cash (used for) provided by operations - discontinued operations (158) 540

Cash used for investing activities - discontinued operations (6) (193)

Cash used for financing activities - discontinued operations (3) (17)

Cash (used for) provided by discontinued operations $ (167) $ 330

Effect of exchange rate changes on cash, cash equivalents and restricted cash (7) 44

Increase (decrease) in cash, cash equivalents and restricted cash $ 1,022 $ (13)

Cash, cash equivalents and restricted cash from continuing operations, beginning of period 757 1,834

Cash, cash equivalents and restricted cash from discontinued operations, beginning of period 3 58

Cash, cash equivalents and restricted cash at beginning of period $ 760 $ 1,892

Cash, cash equivalents and restricted cash from continuing operations, end of period 1,782 1,817

Cash, cash equivalents and restricted cash from discontinued operations, end of period — 62

Cash, cash equivalents and restricted cash at end of period $ 1,782 $ 1,879

DuPont de Nemours, Inc.

Select Segment Information and Non-GAAP Measures

Net Sales by Segment Three Months Ended Six Months Ended

In millions (Unaudited) Jun 30, 2026 Jun 30, 2025 Jun 30, 2026 Jun 30, 2025

Healthcare & Water Technologies $ 856 $ 817 $ 1,662 $ 1,580

Diversified Industrials 963 932 1,838 1,781

Total $ 1,819 $ 1,749 $ 3,500 $ 3,361

Net Sales Variance by Segment Three Months Ended June 30, 2026

Organic Sales Currency Portfolio / Other Total

Percent change from prior year (Unaudited)

Healthcare & Water Technologies 4 % 1 % — % 5 %

Diversified Industrials 3 — — 3

Total 4 % — % — % 4 %

Net Sales Variance by Segment Six Months Ended June 30, 2026

Organic Sales Currency Portfolio / Other Total

Percent change from prior year (Unaudited)

Healthcare & Water Technologies 3 % 2 % — % 5 %

Diversified Industrials 2 1 — 3

Total 3 % 1 % — % 4 %

Operating EBITDA by Segment

Three Months Ended Six Months Ended

In millions (Unaudited) Jun 30, 2026 Jun 30, 2025 Jun 30, 2026 Jun 30, 2025

Healthcare & Water Technologies $ 258 $ 248 $ 502 $ 471

Diversified Industrials 213 199 413 384

Corporate 1

(23) (24) (53) (72)

Total $ 448 $ 423 $ 862 $ 783

1.Corporate includes expenses of the Corporate function not allocated to specific business in the Company.

Equity in Earnings (Loss) of Nonconsolidated Affiliates by Segment Three Months Ended Six Months Ended

In millions (Unaudited) Jun 30, 2026 Jun 30, 2025 Jun 30, 2026 Jun 30, 2025

Healthcare & Water Technologies $ 1 $ — $ 2 $ —

Diversified Industrials — — (1) —

Corporate 1

8 9 7 (6)

Total equity earnings (loss) included in operating EBITDA (GAAP) $ 9 $ 9 $ 8 $ (6)

1.Corporate includes the equity interest acquired in the Delrin® Divestiture transaction.

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures

Reconciliation of "Income from continuing operations, net of tax" to "Operating EBITDA" Three Months Ended Six Months Ended

In millions (Unaudited) Jun 30, 2026 Jun 30, 2025 Jun 30, 2026 Jun 30, 2025

Income from continuing operations, net of tax (GAAP) $ 191 $ 24 $ 341 $ 104

+ Provision for income taxes on continuing operations 75 54 106 71

Income from continuing operations before income taxes $ 266 $ 78 $ 447 $ 175

+ Depreciation and amortization 154 166 309 326

'- Interest income 1, 2

24 18 34 35

'+ Interest expense 3

41 84 81 166

'- Non-operating pension/OPEB benefit (costs) credits 1

(1) — (1) 2

'- Foreign exchange gains (losses), net 1

4 (14) 14 (17)

+ Future Reimbursable Indirect Costs — 25 8 50

+ Corporate DDOB Remediation Costs 6 2 10 5

- Significant items charge (8) (72) (54) (81)

Operating EBITDA (non-GAAP) $ 448 $ 423 $ 862 $ 783

1.Included in "Sundry income (expense) - net".

2.The three and six months ended June 30, 2026 and 2025 excludes accrued interest income earned on employee retention credits. Refer to details of significant items on page 14.

3.The six months ended June 30, 2025 excludes interest rate swap basis amortization. Refer to details of significant items on page 14.

Reconciliation of "Cash provided by operating activities - continuing operations" to Adjusted Free Cash Flow 1 , Transaction-Adjusted Free Cash Flow1 and calculation of "Adjusted Free Cash Flow Conversion" and "Transaction-Adjusted Free Cash Flow Conversion"

Three Months Ended Six Months Ended

In millions (Unaudited) Jun 30, 2026 Jun 30, 2025 Jun 30, 2026 Jun 30, 2025

Cash provided by operating activities (GAAP) 2 - continuing operations

$ 400 $ 74 $ 632 $ 151

Capital expenditures (76) (50) (178) (172)

Adjusted free cash flow (non-GAAP) $ 324 $ 24 $ 454 $ (21)

Separation-related transaction cost and other payments3

2 83 19 136

Transaction-adjusted free cash flow (non-GAAP) $ 326 $ 107 $ 473 $ 115

Adjusted earnings (non-GAAP) 4

$ 257 $ 177 $ 483 $ 331

Adjusted free cash flow conversion (non-GAAP) 126 % 14 % 94 % (6) %

Transaction-adjusted free cash flow conversion (non-GAAP) 127 % 60 % 98 % 35 %

1.Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow are calculated on a continuing operations basis for all periods presented. Refer to the definitions of Non-GAAP metrics on pages 7-8 for additional information.

2.Refer to the Consolidated Statement of Cash Flows included in the schedules above for major GAAP cash flow categories as well as further detail relating to the changes in "Cash provided by operating activities - continuing operations" for the six month periods noted.

3.Other payments for the three months ended June 30, 2026 includes $2 million related of separation-related capital expenditures. Other payments for the six months ended June 30, 2026 includes $5 million of separation-related capital expenditures, $6 million related to restructuring and short-term incentive program payments associated with former senior leadership, and $8 million for Future Reimbursable Indirect Costs (as defined in our Non-GAAP definitions).

4.Refer to page 14 for the Non-GAAP reconciliations of Net income from continuing operations available for DuPont common stockholders to Adjusted Earnings (Non-GAAP).

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures

Significant Items Impacting Results for the Three Months Ended June 30, 2026

In millions, except per share amounts (Unaudited)

Pretax 1

Net Income 2

EPS 3

Income Statement Classification

Reported earnings (GAAP) $ 266 $ 187 $ 1.37

Less: Significant items

Acquisition, integration & separation costs (7) (5) (0.04) Acquisition, integration and separation costs

Restructuring and asset related benefits - net 3 — — Restructuring and asset related charges - net

Other benefits (credits), net 4

(4) (3) (0.02)

Sundry income (expense) - net; Selling, general and administrative expenses

Income tax items 5

— (3) (0.02) Provision for income taxes on continuing operations

Total significant items $ (8) $ (11) $ (0.08)

Less: Amortization of intangibles (68) (53) (0.39) Amortization of intangibles

Less: Non-op pension / OPEB benefit costs (1) (1) (0.01) Sundry income (expense) - net

Less: Corporate DDOB remediation costs

(6) (5) (0.03)

Selling, general and administrative expenses

Adjusted earnings (non-GAAP) $ 349 $ 257 $ 1.88

Significant Items Impacting Results for the Three Months Ended June 30, 2025

In millions, except per share amounts (Unaudited)

Pretax 1

Net Income 2

EPS 3

Income Statement Classification

Reported earnings (GAAP) $ 78 $ 24 $ 0.17

Less: Significant items

Acquisition, integration and separation costs (55) (46) (0.32) Acquisition, integration and separation costs

Restructuring and asset related benefits - net — 1 — Restructuring and asset related charges - net

Interest rate swap mark-to-market loss 6

(27) (21) (0.15) Sundry income (expense) - net

Other benefits (credits), net 7

10 8 0.06 Sundry income (expense) - net

Income tax items 8

— (18) (0.13) Provision for income taxes on continuing operations

Total significant items $ (72) $ (76) $ (0.54)

Less: Amortization of intangibles (74) (58) (0.42) Amortization of intangibles

Less: Non-op pension / OPEB benefit credits — — — Sundry income (expense) - net

Less: Future reimbursable indirect costs (25) (19) (0.14)

Selling, general and administrative expenses

Less: Corporate DDOB remediation costs

(2) — —

Selling, general and administrative expenses

Adjusted earnings (non-GAAP) $ 251 $ 177 $ 1.27

1.Income (loss) from continuing operations before income taxes.

2.Net income (loss) from continuing operations available for DuPont common stockholders. The income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

3.Earnings (loss) per common share from continuing operations - diluted.

4.Includes benefits related to an adjustment of the Donatelle contingent earn-out liability ($8 million pre-tax benefit) and legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($7 million pre-tax cost), and legal costs associated with personal injury cases associated with Corian® Quartz, a product within the Diversified Industrials segment ($8 million pre-tax cost).

5.Reflects the net impact of a valuation allowance release in Europe and a deferred tax asset reversal in the U.S.

6.The three months ended June 30, 2025 includes non-cash mark-to-market loss related to the 2022 Swaps and 2024 Swaps and the interest settlement loss on the 2022 Swaps.

7.Reflects the accrued interest earned on employee retention credits ($3 million pre-tax benefit), benefits related to an adjustment of the Donatelle contingent earn-out liability ($12 million pre-tax benefit) and legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($5 million pre-tax cost).

8.Reflects the income tax impact of certain internal restructurings related to the Electronics Separation.

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures

Significant Items Impacting Results for the Six Months Ended June 30, 2026

In millions, except per share amounts (Unaudited)

Pretax 1

Net Income 2

EPS 3

Income Statement Classification

Reported earnings (GAAP) $ 447 $ 334 $ 2.43

Less: Significant items

Acquisition, integration & separation costs (7) (5) (0.04) Acquisition, integration and separation costs

Restructuring and asset related charges - net (43) (36) (0.26) Restructuring and asset related charges - net

Other benefits (credits), net 4

(4) (3) (0.02)

Sundry income (expense) - net; Selling, general and administrative expenses

Income tax items 5

— 15 0.11 Provision for income taxes on continuing operations

Total significant items $ (54) $ (29) $ (0.21)

Less: Amortization of intangibles (136) (105) (0.77) Amortization of intangibles

Less: Non-op pension / OPEB benefit costs (1) (1) (0.01) Sundry income (expense) - net

Less: Future reimbursable indirect costs (8) (6) (0.04)

Selling, general and administrative expenses

Less: Corporate DDOB remediation costs

(10) (8) (0.06)

Selling, general and administrative expenses

Adjusted earnings (non-GAAP) $ 656 $ 483 $ 3.52

Significant Items Impacting Results for the Six Months Ended June 30, 2025

In millions, except per share amounts (Unaudited)

Pretax 1

Net Income 2

EPS 3

Income Statement Classification

Reported earnings (GAAP) $ 175 $ 102 $ 0.73

Less: Significant items

Acquisition, integration and separation costs (105) (89) (0.63) Acquisition, integration and separation costs

Restructuring and asset related charges - net (39) (32) (0.23) Restructuring and asset related charges - net

Interest rate swap mark-to-market loss 6

50 39 0.28 Sundry income (expense) - net; Interest expense

Other benefits (credits), net 7

13 11 0.08 Sundry income (expense) - net

Income tax items 8

— (2) (0.02) Provision for income taxes on continuing operations

Total significant items $ (81) $ (73) $ (0.52)

Less: Amortization of intangibles (149) (117) (0.84) Amortization of intangibles

Less: Non-op pension / OPEB benefit credits 2 2 0.01 Sundry income (expense) - net

Less: Future reimbursable indirect costs (50) (39) (0.28)

Selling, general and administrative expenses

Less: Corporate DDOB remediation costs

(5) (2) (0.01)

Selling, general and administrative expenses

Adjusted earnings (non-GAAP) $ 458 $ 331 $ 2.37

1.Income (loss) from continuing operations before income taxes.

3.Earnings (loss) per common share from continuing operations - diluted.

4.Reflects the accrued interest earned on employee retention credits ($3 million pre-tax benefit), benefits related to an adjustment of the Donatelle contingent earn-out liability ($14 million pre-tax benefit), legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($10 million pre-tax cost), and legal costs associated with personal injury cases associated with Corian® Quartz, a product within the Diversified Industrials segment ($11 million pre-tax cost).

5.Reflects the 2026 income tax benefit primarily the result of a discrete tax benefit relating to a change in tax classification of a non-U.S. legal entity ($20 million pre-tax benefit).

6.The six months ended June 30, 2025 includes non-cash mark-to-market gain related to the 2022 Swaps and 2024 Swaps and the interest settlement loss on the 2022 Swaps. The six months ended June 30, 2025 also includes basis amortization on the 2022 Swaps ($1 million pre-tax, reflected in "Interest expense" within the Consolidated Statements of Operations).

7.Reflects the accrued interest earned on employee retention credits ($6 million pre-tax benefit), benefits related to an adjustment of the Donatelle contingent earn-out liability ($12 million pre-tax benefit), legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($5 million pre-tax cost).

8.Reflects the income tax impact of certain internal restructurings related to the Electronics Separation.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover Document

Aug. 04, 2026

Document Information [Line Items]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 04, 2026

Entity File Number

001-38196

Entity Registrant Name

DuPont de Nemours, Inc.

Entity Central Index Key

0001666700

Entity Tax Identification Number

81-1224539

Entity Incorporation, State or Country Code

Entity Address, Address Line One

974 Centre Road,

Entity Address, Address Line Two

Building 730

Entity Address, City or Town

Wilmington,

Entity Address, State or Province

Entity Address, Postal Zip Code

19805

City Area Code

(302)

Local Phone Number

295-5783

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration